Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia

Milone, 2009, Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo, Mol Ther, 17, 1453, 10.1038/mt.2009.83

Bridgeman, 2014, CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy, Clin Exp Immunol, 175, 258, 10.1111/cei.12216

Long

Lee, 2013, 4-1BB signaling activates the t cell factor 1 effector/β-catenin pathway with delayed kinetics via ERK signaling and delayed PI3K/AKT activation to promote the proliferation of CD8+ T Cells, PLoS One, 8, e69677, 10.1371/journal.pone.0069677

Grupp, 2015, Durable remissions in children with relapsed/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019) [abstract], Blood, 126, 10.1182/blood.V126.23.681.681

Maude, 2016, Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL [abstract], J Clin Oncol, 34, 3011, 10.1200/JCO.2016.34.15_suppl.3011

Porter, 2016, Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory CLL [abstract], J Clin Oncol, 34, 3009, 10.1200/JCO.2016.34.15_suppl.3009

Grupp, 2016, Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL) [abstract], Blood, 128, 10.1182/blood.V128.22.221.221

Fitzgerald, 2017, Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia, Crit Care Med, 45, e124, 10.1097/CCM.0000000000002053

Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J Clin Invest, 126, 2123, 10.1172/JCI85309

Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222

Lee, 2014, Current concepts in the diagnosis and management of cytokine release syndrome, Blood, 124, 188, 10.1182/blood-2014-05-552729

Lee, 2015, Safety and response of incorporating CD19 chimeric antigen receptor T cell therapy in typical salvage regimens for children and young adults with acute lymphoblastic leukemia [abstract], Blood, 128, 10.1182/blood.V126.23.684.684

Porter, 2015, Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia, Sci Transl Med, 7, 303ra139, 10.1126/scitranslmed.aac5415

Porter, 2014, Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL [abstract], Blood, 124, 10.1182/blood.V124.21.1982.1982

Janetzki, 2009, “MIATA”-minimal information about T cell assays, Immunity, 31, 527, 10.1016/j.immuni.2009.09.007

Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Transl Med, 3, 95ra73, 10.1126/scitranslmed.3002842

Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849

National Comprehensive Cancer Network Guidelines, 2016

National Comprehensive Cancer Network Guidelines, 2017

Porter, 2011, Chimeric antigen receptor therapy for B-cell malignancies, J Cancer, 2, 331, 10.7150/jca.2.331

Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134

Ho, 1993, A phase 1 study of adoptive transfer of autologous CD8+ T lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS, Blood, 81, 2093, 10.1182/blood.V81.8.2093.2093

Walker, 2000, Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection, Blood, 96, 467

Read, 1990, In vivo traffic of indium-111-oxine labeled human lymphocytes collected by automated apheresis, J Nucl Med, 31, 999

Rheingold, 2015, Efficient trafficking of chimeric antigen receptor (CAR)-modified T cells to CSF and induction of durable CNS remissions in children with CNS/combined relapsed/refractory ALL [abstract], Blood, 126, 10.1182/blood.V126.23.3769.3769

Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci Transl Med, 6, 224ra25, 10.1126/scitranslmed.3008226

Teachey, 2016, Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia, Cancer Discov, 6, 664, 10.1158/2159-8290.CD-16-0040

Maude, 2016, Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL [abstract], J Clin Oncol, 128, 217

Brusa, 2013, The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia, Haematologica, 98, 953, 10.3324/haematol.2012.077537

Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B-cell ALL patients, J Clin Invest, 126, 2123, 10.1172/JCI85309

Schuster, 2017